Surged on evidence therapy useful against Omicron

$Vir Biotechnology(VIR.US)$ climbed after it said it has more data showing that its COVID-19 anti-body therapy is effective against Omicron variant. The company said sotrovimab has also been designed to achieve high concentration in the lungs to ensure optimal penetration into airway tissues affected by the virus and to have an extended half-life.